Loading...
Loading...
Astex Pharmaceuticals, Inc.
ASTX today announced topline results from the ongoing phase 2 of
SGI-110 in patients with AML and MDS. The Phase 2 study is a randomized study
of SGI-110 given either as 60 or 90 mg/m2 daily for 5 days in a 28-day course.
As of end of June data cutoff, 67 AML patients had a minimum follow up of 3
months (50 patients representing the complete cohort of relapsed/refractory
AML, and 17 patients in the treatment-naive elderly AML not suitable for
induction chemotherapy cohort). The primary endpoint is overall remission rate
(Complete Remission or CR; Complete Remission with Incomplete hematologic
recovery or CRi/CRp). There were 8 remissions in relapsed/refractory AML and 9
remissions in treatment-naive elderly AML for an overall complete remission
rate (CR, CRi/CRp) of 17/67 or 25%. The detailed results have been submitted
for presentation to the American Society of Hematology (ASH) meeting to be
held later this year during December 7-10 in New Orleans, LA.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in